Skip to Main Content

Paper Details

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Clin Cancer Res
120
2008
BRAF, BRAF mutations, PATIENTS, Sorafenib, advanced cancer, carboplatin, hematologic toxicities, melanoma, paclitaxel, patients, solid tumors, sorafenib, tumor

Datasets

Release 1.2